

**2011 GROVER CONFERENCE ON RISK FACTORS IN PULMONARY HYPERTENSION:  
GENDER, SEX HORMONES, OBESITY, NOVEL GENETIC INFLUENCES AND RISK FACTORS**

**COURSE SCHEDULE**

**Wednesday, September 7, 2011**

**12:00 pm - Arrivals**  
**6.00 pm - Welcome Reception and Dinner**

**Thursday, September 8, 2011**

**Session I (Part I): Genetic Risk Factors**  
**Chairs: Richard Trembath, Nicholas W. Morrell, Jim Loyd**

**6:55-7:55 am Breakfast**

**8:00 am Welcome and Introduction**

E. Kenneth Weir, MD, Minneapolis, MN (University of Minnesota)

**8:10 am Update and Overview of Genetic Influences** (Including update on New Genetic Studies vs. Association Studies).

James E. Loyd, MD, Nashville, TN (Vanderbilt University Center for Lung Research)

**8:45 am Genetic Risk Factors for Portopulmonary Hypertension in Patients with Advanced Liver Disease.**

K.E. Roberts, MD, Boston, MA (Tufts University Medical Center)

**9:20 am Novel Loci Interacting Epistatically With Bone Morphogenetic Protein Receptor 2 Cause Familial Pulmonary Arterial Hypertension.**

David A. Greenberg, PhD, New York, NY (Columbia University)

**9:55 am Break (10 min)**

**10:05 am Estelle Grover Lecture**

**A Single-Nucleotide Polymorphism in the TRPC6 Gene Promoter Associated with Idiopathic Pulmonary Arterial Hypertension**

Jason X-J Yuan, MD, PhD, San Diego, California (University of California San Diego)

**10:55 am microRNAs-control of Essential Genes: Recent Implications.**

William T. Gerthoffer, PhD, Mobile, Alabama (University of South Alabama)

**11:30 am Risk Factors in PPHN**

David N. Cornfield, MD, Palo Alto, CA (Stanford University)

**12:05 pm The Hypoxic Pulmonary Hypertensive Gene**

John H. Newman, MD, Nashville, TN (Vanderbilt University School of Medicine)

**12:40 pm Lunch**

**Session I (Part II) Obesity as a Risk Factor**  
**Chairs: Norbert Voelkel, Matt Thomas, Novartis, Troy Stevens**

**3:00 pm Metabolic syndrome and PPARgamma**

Antonio Vidal-Puig, MD, Cambridge, UK (University of Cambridge)

**3:45 pm Obesity and Thyroid Disease in Women with Severe Pulmonary Hypertension**

Norbert Voelkel, MD, Richmond, VA (Virginia Commonwealth University Medical Center)

**4:20 pm Etiologies and Comorbidities in pulmonary hypertension: Insight from the REVEAL Registry**  
David A. Badesch, MD, Aurora, CO (University of Colorado Denver)

**4:55 pm Exercise Capacity, COPD and Pulmonary Hypertension**  
Matthew Thomas, PhD, UK (Novartis Institutes for BioMedical Research)

**6:30 pm Dinner**

**Friday, September 9, 2011**

**Session II (Part I). Endogenous factors and PAH**  
**Chairs: Sami Said, Ken Weir**

**6:55-7:55 am Breakfast**

**8:05 am Terry Wagner Lecture**  
**Vasoactive Intestinal Peptide Gene is a Key Modulator of Pulmonary Vascular Remodeling and Inflammation**  
Sami I. Said, MD, Stony Brook, NY (SUNY at Stony Brook)

**8:55 am C-type natriuretic peptides in the human circulation and relation to cardiac function**  
A. Mark Richards, MD, PhD, Otago, New Zealand (University of Otago, New Zealand)

**9:30 am Adiponectin Deficiency: A Model of Pulmonary Hypertension Associated with Pulmonary Vascular Disease**  
Kenneth Walsh, PhD, Boston, MA (Boston University School of Medicine)

**10:05 am Break (10 min)**

**10:15 am Apelin and Pulmonary Hypertension**  
Charlotte Andersen, Copenhagen, Denmark (Pfizer Europe)

**10:50 am Adiponectin and Pulmonary Vascular Remodeling**  
Benjamin D. Medoff, MD, Boston, MA (Massachusetts General Hospital)

**12:00 pm Lunch**

**Session III (Part I). Estrogen metabolism and disease penetrance**  
**Chairs: John West  
Karen Fagan, Mark Gillespie**

**4:00 pm Alterations in estrogen metabolism: Implications for higher penetrance of FPAH in females**  
Eric D. Austin, MD, Nashville, TN (Vanderbilt University)

**4:35 pm Young Investigator Award Talk chosen from submitted abstract**  
TBD

**5:00 pm Gene Expression and CYP1B1 in BMPR2 Mutation Carriers with and without Evidence of Pulmonary Arterial Hypertension suggests Pathways Relevant to Disease Penetrance.**  
James D. West, PhD, Nashville, TN (Vanderbilt University School of Medicine)

**5:35 pm Young Investigator Award. Talk chosen from submitted abstract**

**6:30 pm Dinner**

**Saturday, September 10, 2011**

**Session III (Part II) Epigenetics**  
**Chairs: Stephen Archer, Ivan McMurtry, Mandy MacLean**

**6:55-7:55 Breakfast**

**8:05 am Epigenetics and Cardiovascular Disease**

Virginia H. Huxley, PhD, Columbia, MO (National Center for Gender Physiology, University of Missouri-Columbia)

**8:50 am John Reeves Lecture**

Epigenetic Attenuation of Mitochondrial Superoxide Dismutase 2 in PAH  
Stephen L. Archer, MD, Chicago, IL (University of Chicago)

**9:35 am Break (10 min)**

**Session III (Part III) Sex Hormones and PAH**

**9:45 AM Estradiol Metabolites and Progestins in Experimental PAH**

Stevan P. Tofovic, DSc, MD, Pittsburgh, PA (University of Pittsburgh School of Medicine)

**10:20 am Dehydroepiandrosterone and Experimental PAH**

Masahiko Oka, MD, PhD, Mobile, AL (University of South Alabama)

**10:55 am Serotonin, Estrogens and PAH**

Mandy R. MacLean, PhD, Glasgow, UK (University of Glasgow)

**11:30 am PPHN, serotonin as risk factor**

Cassidy Delaney, MD, Aurora, Colorado (University of Colorado Hospital)

**12:30 pm Lunch**

**Session IV**  
**Risk Factors in Pulmonary Hypertension: Gender, Sex Hormones, Obesity, Novel Genetic Influences, and Novel Risk Factors**  
**Facilitators/Chairs: Karen Fagan, Larissa Shimoda,**

**4:00 pm Abstract/Poster Review**

**7:00 pm Dinner**

**Sunday 11<sup>th</sup> September**

**Session V**  
**2011 Risk Factors and Responsiveness to Current and Emerging Therapies**  
**Chairs: John Westwick, Kurt Stenmark, Jason Yuan**

**7:00-8:00 am Breakfast**

**8:00 am Biomarkers in PAH – can we predict responsiveness to specific therapies?**

Martin Wilkins, MD, London UK (Imperial College)

**8:35 am Prostacyclin-Mediated Changes to Inflammation in PAH**

Kurt R. Stenmark, MD, Denver, CO (University of Colorado Denver)

**9:05 am The effect of Sildenafil Treatment on TRPC Channels**  
Jian Wang, PhD, Baltimore, MD (Johns Hopkins University)

**9:40 am Break (10 min)**

**9:50 am Gender Differences in Vascular Reactivity to Endothelin-1**  
Rita C. Tostes, PhD, Sao Paulo, Brazil (University of Sao Paulo)

**10:25 am The Role of Medical Therapy in Non-PAH PH**  
Marius M. Hoeper, MD, Hannover, Germany (Hannover Medical School)

**11:00 am Vascular Progenitors in PAH – Biomarkers, Targets or Therapy?**  
Nicholas W. Morrell, MD, Cambridge, UK (Cambridge University)

**11:35 am Risk Factors and Responsiveness to Therapies in the Modern Era of PAH Treatment**  
Oliver Sitbon, MD, Paris, France (Hopital Antoine Beclere)

**12:10 pm Closing summary (10 min)**  
Mandy MacLean and Karen Fagan

**12:30 Lunch**

**Conference adjourns after lunch**